Core Insights - Journey Medical achieved a significant milestone in 2025 with the commercial launch of EMROSI, an oral treatment for rosacea, and reported improved profitability metrics as the product gains traction [5][6] Product Performance - EMROSI generated approximately $14.7 million in net sales during the three quarters it was available in 2025, with around 53,000 total prescriptions written [4][8] - The refill behavior for EMROSI improved, with a ratio of 1.4 refills per new prescription by the end of 2025, indicating strong ongoing demand [1][8] - The company ended 2025 with over 3,500 unique dermatology prescribers for EMROSI, surpassing its initial goal [2] Financial Results - Full-year 2025 revenue rose to $61.9 million, a 10% increase from $56.1 million in 2024, driven by the launch of EMROSI [6][17] - The gross margin for 2025 was reported at 66.2%, up from 62.8% in 2024, attributed to a favorable product mix and lower inventory costs [21] - The GAAP net loss narrowed to $11.4 million in 2025, compared to a loss of $14.7 million in 2024, reflecting improved financial performance [21] Market Access and Coverage - Journey Medical reported access to approximately 100 million commercial covered lives, with contracts with two of the top three U.S. group purchasing organizations (GPOs) [7][11] - The company expects to contract with the third major GPO by early second quarter of 2026, which is anticipated to enhance market access [11] Future Outlook - The company anticipates remaining adjusted EBITDA positive in 2026, supported by expected sales growth and the leverage of its commercial organization [20] - Journey plans to launch one to two additional dermatology products later in 2026, indicating a focus on portfolio expansion [21][22] - Management expects gradual improvement in gross-to-net dynamics as formulary milestones are reached throughout 2026 [12][20]

Financial Data and Key Metrics Changes - Total revenues for 2025 were $61.9 million, a 10% increase from $56.1 million in 2024, driven by the successful launch of EMROSI [17] - Gross margins improved to 66.2% in 2025 from 62.8% in 2024, reflecting a favorable product mix and lower inventory costs [17] - GAAP net loss narrowed to $11.4 million ($0.47 per share) in 2025 from a loss of $14.7 million ($0.72 per share) in 2024 [18] - Adjusted EBITDA was positive at $2.9 million for 2025, compared to $800,000 in 2024, indicating progress towards sustainable profitability [18] Business Line Data and Key Metrics Changes - EMROSI achieved $14.7 million in net sales during its first three quarters on the market, with approximately 53,000 prescriptions written [5][7] - The total prescription volume for EMROSI grew nearly 50% sequentially in Q4 compared to Q3 [8] - The company ended 2025 with approximately 3,500 unique prescribers for EMROSI, surpassing its initial goal of 3,200 [9] Market Data and Key Metrics Changes - Approximately 100 million commercial covered lives have access to EMROSI, with contracts in place with two of the top three group purchasing organizations in the U.S. [10] - The company anticipates contracting with the third major GPO by late Q1 or early Q2 of 2026 [10] Company Strategy and Development Direction - The company plans to launch one or two additional dermatology products in 2026 to augment its revenue growth [15][25] - Focus on improving profitability through disciplined expense management and margin expansion as EMROSI's commercial footprint grows [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued sales growth and expects to remain adjusted EBITDA positive in 2026 [7] - The company anticipates improved reimbursement rates and reduced reliance on co-pay bridging programs as coverage expands [11] - Management highlighted the importance of EMROSI's clinical efficacy and safety profile in driving demand and patient refill behavior [12] Other Important Information - The company ended 2025 with a cash position of approximately $24 million, up from $20.3 million at the end of 2024 [18] - Working capital at year-end was $29.4 million, an increase of $16.4 million from the previous year [19] Q&A Session Summary Question: Trends in EMROSI prescriptions for Q1 - Management noted that Q1 typically sees a slowdown due to insurance deductible resets and severe weather but expects Q1 prescriptions to surpass Q4 numbers [28][29] Question: Expectations for Q2 prescriptions - Management anticipates strong momentum in Q2, with expectations for prescription growth to continue [30] Question: Gross-to-net revenue predictions - Management indicated that gross-to-net figures are expected to improve as reimbursement progresses and the mix of reimbursed prescriptions changes [34][35] Question: Inventory movement and accounts receivable - Management confirmed that the increase in accounts receivable was due to timing and that most cash has been collected [66] Question: Future product launches - Management described upcoming product launches as incremental additions to the portfolio, aimed at supporting the base business [70]

Core Viewpoint - Crescita Therapeutics Inc. has entered into a definitive agreement to be acquired by ClinActiv Holdings Inc. in an all-cash transaction at a significant premium, with a target purchase price of $0.80 per share, representing a 74% premium over the five-day volume weighted average price prior to the announcement [1][2]. Transaction Details - The purchase price of $0.80 per share is subject to adjustments based on the company's net working capital at closing, with a minimum price of $0.75 per share [1]. - The transaction will be executed through a court-approved statutory plan of arrangement and requires approval from at least two-thirds of the votes cast by shareholders [7]. - The expected closing of the transaction is in the second quarter of 2026, after which Crescita's shares will be delisted from the TSX [8]. Shareholder Support - Significant shareholders, including senior management and directors holding approximately 33% of outstanding shares, have signed agreements to vote in favor of the arrangement [3]. - The Board of Directors has unanimously recommended that shareholders vote for the arrangement after evaluating strategic alternatives [6]. Fairness Opinion - Bloom Burton Securities Inc. provided a fairness opinion stating that the purchase price is fair to Crescita's shareholders from a financial perspective [4]. Strategic Intent - ClinActiv aims to build a global dermatology platform through this acquisition, leveraging Crescita's integrated platform and expertise in dermatology [5]. - The transaction is seen as a strategic move to enhance Crescita's growth potential through access to ClinActiv's commercial networks and product portfolios [5]. Post-Closing Reorganization - Following the closing, a reorganization will occur where ClinActiv retains ownership of Crescita's commercial skincare and contract manufacturing business, while the management group will acquire the remaining business [10]. - The Board has concluded that this reorganization provides a net benefit to Crescita's shareholders [10].

Core Insights - Obagi Medical has selected Schweiger Dermatology as a key partner for its Aesthetics Leadership with the Hyaluronic Acid (ALOHA) Program, emphasizing clinical excellence and rapid access to care [1] Company Overview - Obagi Medical is recognized as a leading innovator in physician-dispensed skincare and aesthetic solutions, with over 35 years of experience in the industry [7] - Schweiger Dermatology is a prominent national dermatology practice that offers a range of services including medical, cosmetic, and surgical dermatology, focusing on high-quality, personalized care [8] - Waldencast plc, the parent company of Obagi Medical, aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands [9] Partnership Details - The partnership will generate real-world data to translate clinical safety and efficacy from FDA pivotal trials into everyday practice [2] - The ALOHA Program includes a Phase 4 clinical study and a real-world evaluation program to enhance patient satisfaction and provider-patient relationships [3] - Initial program activities are expected to commence in early 2026, with findings to be presented at internal leadership meetings and key industry conferences [4] Product Information - Obagi saypha MagIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology to create a stable hyaluronic acid matrix, aiming for natural-looking results and high performance [5]

Core Insights - Galderma conducted a global survey revealing that over 50% of peri- and post-menopausal women learned about menopause's effects on skin through personal experience, primarily in their 40s, with over 30% wishing they had known in their 30s [1][2][4] Group 1: Survey Findings - The survey included over 4,300 women aged 45-60 from nine countries, highlighting that women experienced an average of three skin changes since menopause, with 59% reporting lines and wrinkles on the face and 33% on the body [6][12] - The main skin changes reported were loss of firmness and elasticity (58% on the face, 54% on the body), increased dryness (56% on the face, 58% on the body), and a duller skin tone (40% on the face, 30% on the body) [6][7] Group 2: Impact on Wellbeing - The survey indicated that menopause-related skin changes negatively impacted women's self-perception, with 60% feeling less attractive, 57% feeling anxious, and 55% feeling less confident [4][12] - Aesthetic treatments were viewed as effective solutions, with 49% of women currently using them for menopause-related skin changes, while 26% used them for prevention [12] Group 3: Aesthetic Treatments - Galderma plans to include menopausal status in clinical trials to better understand how injectable aesthetic treatments can address menopause-related skin changes [2][5] - Treatments such as hyaluronic acid and biostimulators are highlighted for their potential to enhance hydration, restore collagen and elastin, and improve skin quality [5][9] Group 4: Company Commitment - Galderma aims to elevate awareness and advance aesthetic solutions for menopause-related skin changes through collaboration with experts and community education [8][10] - The company is positioned as a leader in dermatology, focusing on innovative, science-based solutions to meet the needs of women during menopause [10][8]

Core Insights - Obagi Medical has selected Platinum Dermatology Partners as the first partner for its ALOHA Program, emphasizing a commitment to clinical evidence and practice dissemination [1][5] Company Overview - Obagi Medical is a leading innovator in physician-dispensed skincare and aesthetic solutions, part of Waldencast plc, with over 35 years of experience in advanced skincare [6] - Platinum Dermatology Partners operates over 120 locations with nearly 400 providers across multiple states, focusing on exceptional dermatology practices [7] - Waldencast plc aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands [8] Partnership Details - The partnership aims to generate real-world data to translate clinical safety and efficacy from FDA trials into everyday practice [2] - The ALOHA Real-World Program will provide hands-on experience with Obagi saypha MagIQ, enhancing patient satisfaction and provider relationships [3] - Initial findings from the program will be presented at the annual Platinum Summit and key industry conferences to showcase the product's real-world impact [4] Product Information - Obagi saypha MagIQ™ utilizes proprietary MACRO Core Technology for a stable hyaluronic acid matrix, designed for natural-looking results and high performance [5]

Fund Performance - The Summers Value Fund LP achieved a net return of 20.4% in Q3 2025, outperforming the Russell 2000 Index ETF (12.4%) and the Russell 2000 Value Index ETF (12.5%) [2] - Year-to-date, the Fund is up 4.9%, lagging behind the IWM (10.3%) and IWN (8.9%) [2] - Since inception, the Fund has delivered a 12.2% annualized net return compared to 6.8% for IWM and 6.1% for IWN [2][3] Healthcare Sector Overview - The healthcare sector has faced challenges leading to underperformance against broader indexes, influenced by regulatory uncertainty from new FDA leadership and budget pressures at federal agencies [4] - Investors withdrew approximately $13 billion from healthcare funds in 2025, indicating a record annual outflow, while large-cap stocks saw $224 billion in inflows [5] - Despite negative sentiment, the healthcare sector is viewed as defensive and growing, with potential for disciplined investors to find opportunities [5][6] Investment Opportunities - The Fund has increased exposure to biopharma stocks, anticipating outperformance due to an innovation cycle and potential acquisitions by large-cap companies [6] - Notable contributors to the Fund's performance in Q3 included Zimvie (124% acquisition premium), Liquidia (strong sales of Yutrepia), and Consensus Cloud Solutions (return to positive revenue growth) [7] - The Fund initiated a position in uniQure following promising Phase 3 results for its gene therapy drug, which showed a 75% reduction in disease progression [9] Position Updates - Journey Medical, with a market cap of $175 million, launched Emrosi for rosacea treatment, with annualized sales approaching $30 million and potential peak sales exceeding $100 million [12] - Ligand Pharmaceuticals, valued at $3.7 billion, operates as a royalty aggregator and is expected to see strong performance from its drugs Ohtuvaryre and Filspari, with blockbuster potential [13][14] - The Fund's top five holdings include Electromed, Consensus Cloud Solutions, Liquidia, Spok Holdings, and Ligand Pharmaceuticals, with a significant allocation to pharmaceutical and biotechnology stocks [10]

Core Insights - Galderma, a leader in the dermatology category, will present updates from its portfolio at the 34th European Academy of Dermatology and Venereology (EADV) congress in Paris from September 17-20, 2025 [1] - The company is committed to addressing various skin conditions and will showcase 12 abstracts, including data on sensitive skin, prurigo nodularis, and atopic dermatitis [1] Company Focus - Galderma emphasizes its dedication to dermatology by participating in significant industry events like the EADV congress [1] - The presentation of 12 abstracts indicates a robust research and development pipeline aimed at enhancing treatment options for skin conditions [1]

Strategic Acquisition - LEO Pharma agreed to acquire global rights for skin disease drug Spevigo from Boehringer [1] - The acquisition strengthens LEO Pharma's portfolio [1] IPO Plans - LEO Pharma is planning an IPO in 2026 [1] Industry Focus - LEO Pharma is a Danish dermatology specialist [1]

Does Red Light Therapy Work? We Had Dermatologists Weigh Inhttps://t.co/l1iluk4Mu8 https://t.co/K84uM7CKjR ...